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Diabetic Retinopathy and 
Blindness: An Epidemiological 
Overview
Maya Georgieva Pandova
Abstract
Prevalence of diabetes is rising worldwide. In the course of the last 20 years, 
blindness and low vision due to diabetic eye complications have increased in large 
regions in Eastern Europe, North Africa/Middle East, Asia, Latin America, and 
Oceania. The magnitude and trends of vision-threatening disease are presented. 
Systemic risk factors for progression to sight-threatening disease are reviewed. The 
impact of economic and cultural background on early diagnosis and adherence to 
treatment is highlighted. Current management of diabetic macular edema, prolif-
erative diabetic retinopathy, neovascular glaucoma, and cataract surgery of diabetic 
patients is outlined, and its contribution to preventing vision loss is reviewed.
Keywords: diabetic retinopathy, trends, blindness, risk factors, treatment, visual 
outcome
1. Introduction
“It is a truism that each solution brings its own problems. Diabetic retinopathy in 
survivors of longstanding diabetes…represents the price paid for conquests that are 
not quite complete. The prolongation of life without corresponding prolongation 
of health, is loaded with intractable problems.” commented Arnold Sorsby on the 
“striking increase” of blindness from diabetes for both men and women between 
1948 and 1962. [1]
The next six decades saw intensive research in the pathogenesis and epidemiol-
ogy of diabetic eye disease and the introduction of laser photocoagulation in the 
early treatment of diabetic retinopathy, pars plana vitrectomy for traction, and 
rhegmatogenous retinal detachment and intravitreal pharmacotherapy in the 
management of diabetic macular edema (DME), all addressing prevention of vision 
loss in these patients.
2. Magnitude of blindness due to diabetic eye disease
Reports on the vision loss attributable to diabetes in the 1980s and 1990s vary 
greatly in their methodology—some have derived clinical information from hospital 
series, and others have reviewed the registry forms of certified disabled persons 
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from the records of societies of the blind; there are reviews on patients referred to 
low vision rehabilitation centers and finally some present data from population-
based observational studies. Each source has its shortcomings. Definitions in 
registry databases depend on the national disability legislation and often differ 
from the categories for blindness and low vision in the International Classification 
of Diseases (ICD)—Ninth and Tenth Revisions—that were in use at that time. Many 
authors stress on the difficult task of identifying the onset and the main cause of 
vision loss in diabetic patients with multiple ophthalmic comorbidities, especially 
in their final stages. For a long period, well into the 1980s, non-ophthalmic profes-
sionals were allowed to certify blind persons for registration that raises reservations 
regarding the accuracy of the cause. A common concern is the inability to determine 
the number of underreported and unregistered diabetic persons with vision loss 
as registration is voluntary, and it depends on clinical, social, and cultural factors; 
many authors have noted a rise in the incidence rates of DR with the arrival of more 
consultants in the area, after upgrade in the financial benefits and social support 
for legally blind or following campaigns to improve public awareness and reduce 
stigmatization.
Hospital series analyze clinical data collected in specialized diabetic units over 
long periods in a consistent manner and provide reliable estimate on the severity 
and progression of vision loss; however, extrapolations of their findings for the 
population beyond their urban region are seldom possible.
Publications from the UK, Denmark, and Sweden demonstrate a decrease in 
the incidence of new blindness from DR in the 1980s and 1990s [2–5]; however it 
remained unchanged between 1967 and 1991 in Italy and Avon, UK [6, 7]. In their 
review on the trends in blindness in Singapore, See et al. [8] present a sharp increase 
in the prevalence of diabetes in the age between 15 and 69 from 1.99% in 1975 to 
8.6% in 1992 and a rise in the proportion of blindness from diabetic complications 
from 5% in the 1950s to 47.3% in the 1980s.
Global data on blindness [9, 10], a review report of the WHO programme for 
prevention of blindness, summarized available information from population-based 
assessment of visual loss and its causes. DR was not among the four major causes for 
blindness and low vision globally and ranked between the first and fourth only in 
Western Europe, the former socialist economies of Europe, North America, Latin 
America, and Oceania. The authors note the lack of relevant epidemiological data 
for some specific causes of blindness; however they emphasize that this disease is 
“generally recognized to be the leading cause of blindness among those in working 
age in developed countries and rapidly emerging in urban areas of the developing 
world.”
An update on the estimates of global and regional blindness and low vision was 
published in 2004 presenting results of new population-based studies and other 
sources of information. The proportion of DR rose to 4.8% globally, and it was 
ranked fifth as a cause of blindness, with significant regional variations reaching 
17% for North America and Australia, 17–15% in Europe, and 3–7% in the rest 
of the world where the majority of vision loss was due to cataract, glaucoma, and 
corneal opacities as complications of trachoma [11].
A meta-analysis of all available population-based studies performed world-
wide from 1990 to 2010 [12] estimated that 833,690 people were blind and 3.7 
million were visually impaired globally in 2010 due to DR. The highest number 
of blind diabetic patients was in South Asia, 295,000; North Africa/Middle East, 
108,000; Eastern sub-Saharan Africa, 50,000; and Western sub-Saharan Africa, 
66,000. The age-standardized prevalence of blindness from diabetic retinopathy 
in people over the age of 50 years was 0.05% globally, reaching 0.19% in Western 
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sub-Saharan Africa, 0.16% in North Africa/Middle East, 0.14% in Eastern 
sub-Saharan Africa, and 0.12% in Southeast and East Asia. Moderate and severe 
vision impairment due to DR affected 3174 million, and the largest number of 
them were in South Asia, 1450 million, followed by North Africa/Middle East, 
336,000; Eastern Asia, 279,000; Western Europe, 225,000; Western sub-Saharan 
Africa, 193,000; Eastern Europe, 166,000; Eastern sub-Saharan Africa, 128,000; 
and Central Latin America, 109,000. The age-standardized prevalence of moder-
ate and severe vision impairment due to DR in people over the age of 50 years 
was 1.9% globally and was highest—0.51%—in South Asia, 0.50% in Western 
sub-Saharan Africa, 0.44% in North Africa/Middle East, 0.36% in Southern Latin 
America, 0.33% in Central sub-Saharan Africa, 0.32% in Andean Latin America, 
0.31% in Eastern sub-Saharan Africa, and 0.26% in Oceania [13]. From 1990 to 
2010, the number of blind diabetics had increased by 27% and those with visual 
impairment by 64% globally. Globally, age-standardized prevalence of blind-
ness and vision impairment of diabetics over the age of 50 years was relatively 
unchanged in the course of these 20 years. It reduced by half in high-income 
Pacific Asia, Europe, Australasia, and North America; however it remained high 
in large, densely populated regions of Africa and Asia with rapidly increasing 
prevalence of diabetes.
A continuation of this systematic review and meta-analysis of data from 261 
population-based studies published till 2014 [14] observed that while blind-
ness to all causes reduced between 1990 and 2015, DR was the only one with 
prevalence that increased by 7.7% for blindness and by 28.6% for impairment. 
The proportion of vision loss attributable to diabetes ranked seventh in 2015 at 
1.06% (0.15–2.38) globally and was highest in Eastern Europe, 4.91%, followed by 
Australasia, high-income North America, high-income Pacific Asia, and Central 
Asia. The contribution of DR to moderate and severe vision impairment was 
1.30% (0.20–2.93) and reached 5.06% in Eastern Europe, followed by Australasia, 
high-income North America, high-income Pacific Asia, and Central Asia. The 
same regions were leading in the percentage of blindness and low vision due to 
DR for people over the age of 50 years. The age-standardized prevalence of blind-
ness from DR across all ages was relatively low, in the range of 0.00–0.01 (0.00–
0.02), and was considerably higher for vision impairment, 0.03% (0.00–0.13), 
with Eastern Europe ranking first at 0.11%, Central Asia, 0.09%; Southern Latin 
America, 0.08%; and North Africa/Middle East and Australasia, 0.07%. The age-
standardized prevalence of blindness of diabetics over the age of 50 was 0.02% 
(0.00–0.07) and was highest in North Africa/Middle East, Eastern Europe, and 
Central Asia. The age-standardized prevalence of low vision in the same age 
group was 0.13% (0.01–0.48), and the same regions were most affected. For the 
first time, this report presented data on the gender differences in the cause and 
magnitude of vision loss and demonstrated that the relative risk of blindness and 
vision impairment in diabetic women as compared to men was 2.52. The number 
of people with blindness due to diabetic retinopathy was estimated at 400,000 
(0–1.5 million) and low vision 2.6 million (0.2 million—9.9 million), both almost 
doubled since 1990. The projections for diabetic complications for 2020 are for 
further increase, and the largest number of people are expected to reside in North 
Africa/Middle East, 73,000 blind and 4,480,000 with low vision; Eastern Europe, 
47,000 blind and 362,000 with low vision; Western Europe, 46,000 blind and 
422,000 with low vision; East Asia, 41,000 blind and 400,000 with low vision; 
and Southeast Asia, 30,000 blind and 216,000 with low vision. The authors 
point out that the prevalence of any DR and sight-threatening DR was similar 
in men and women, whereas their analysis suggested female preponderance for 
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vision-impairing DR. They attribute this discrepancy to the use of aggregated 
data for both genders combined in some of the studies and highlight the need 
for further research into the gender differences. There are considerable regional 
variations in the blindness and low vision due to DR, and they are related to the 
prevalence of diabetes in the population and the life expectancy of the diabetic 
patients. In the Middle East, Kuwait, for example, the prevalence of diabetes has 
reached 20–25% of the whole population and over 50% after the age of 60 years. 
In some regions, in particular in South Asia, the life expectancy of diabetic indi-
viduals is reduced, they do not have the chance to develop retinopathy as sequela 
of the disease, and the prevalence of debilitating retinopathy is low despite the 
high proportion of diabetes.
A detailed meta-analysis of the trends in vision loss in high-income countries in 
Pacific Asia, Australasia, North and Latin America and Western Europe, as well as 
Central and Eastern Europe from 1990 to 2015 [15] presented a relatively low and 
stable prevalence of blindness due to DR for all ages in the range of 0.01–0.02% in 
the whole super-region; however the rates for moderate and severe visual impair-
ment varied in the range from 0.6–0.7% in most of the high-income countries to 
1.6% in Eastern Europe and Australasia. The crude prevalence of blindness among 
diabetics over 50 years was in the range of 0.02–0.03% in the high-income coun-
tries, 0.04% in Central Europe, and 0.06–0.07% in Eastern Europe, and visual 
impairment was lowest in Western and Central Europe and Pacific Asia, followed 
by North America and Australasia and highest in Eastern Europe. The projections 
for 2020 were for stable or slightly reduced prevalence of blindness and gradual 
increase of patients with visual impairment in the super-region.
Vision loss in the multiethnic population of Singapore over the age of 40 years 
was investigated in a series of population-based studies that demonstrated 
relatively high prevalence of diabetes in the sample—29.5%; DR was the second 
leading cause of vision impairment and blindness, and Indians and Malays were 
more affected than the Chinese. The authors point out that DR-related blind-
ness in these three ethnicities in Singapore was less than the mainland Southern 
Indians, mainland Han Chinese, and peninsula Malays, and they attribute this 
to better access to qualified eye screening and care in Singapore. Diabetes was a 
significant contributing factor for visual impairment generally and increased the 
risk by 2.96 for people below the age of 60 years and 12.70 times for those over 
60, particularly for females and patients with cognitive impairment and deafness, 
a tendency that was consistently observed across Malays, Indians, and Chinese. 
Diabetes in combination with other comorbidities, hypertension, hyperlipidemia, 
cardiovascular, or renal disease, was associated with higher risk of vision loss, up 
to 9.51 for people younger than 60 years and 26.56 for those older than 60, par-
ticularly for Indians, and an interaction effect for concomitant diabetes and renal 
diseases [16].
Vision-threatening DR (VTDR) is a compound term used in the literature for 
the presence of proliferative disease grading over level 60 by EDTRS scale and its 
modification and/or macular edema in its various stages [17, 18], and its magnitude 
is essential for planning the life-long management of these patients and prevention 
of blindness. The prevalence and risk factors of VTDR were estimated in a large 
meta-analysis of 38 population-based studies from Australia, the USA, Europe, and 
Asia involving 42,091 participants from 20 to 79 years with diabetes. There was no 
discernible sex difference in the age-standardized prevalence of VTDR, 11.7%; it 
was highest among African Americans, 16.89%; followed by Caucasians, 15.45%; 
and Hispanics, 10.35, and was lowest in South Asians—5.2%. Duration of diabetes 
(DM) was associated with rapidly increasing prevalence from 3.53% for DM less 
than 10 years to 17.78% for 10–20 years and up to 87% for more than 20 years. 
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Metabolic control, estimated by the levels of HbA1c, directly affected the extent 
of VTDR—the disease doubled in patients with levels between 7.1 and 8.0% and 
tripled among those with more than 9.0%. Elevated blood pressure over 140/90 
and hypercholesterolemia over 4.0 mMol/L elevated the risk of VTDR twice, 
particularly for macular edema. Individuals with type 1 diabetes for more than 
20 years were 15 times more likely to have proliferative diabetic retinopathy (PDR) 
(15.3 [11.3–20.8]), 5 times more likely to have DME (4.83 [3.71–6.30]), and 8.7 times 
more likely to have VTDR (8.69 [7.10–10.63]) than those with type 2 diabetes for less 
than 10 years. On a positive note, the prevalence of VTDR reduced from 15.62% in 
studies where the fundus photographs were taken before the year 2000 to 7.86% in 
the studies with assessment of the patients after 2000.
This pivotal work highlighted the importance and cutoff levels of the systemic 
factors associated with progression of DR to sight-threatening stage and the need 
for close collaboration with the treating diabetology team. It outlined the profile 
of the patients at risk of vision loss with their features—type and duration of 
diabetes, levels of metabolic control, hypertension, and hypercholesterolemia. The 
role of ethnicity was limited to the populations studied, and the authors note the 
absence of studies from Middle East, Africa, and South America that could affect 
the accuracy of their global estimates. The differences in the rates of VTDR in the 
various populations could be due to both genetic factors and access to health care. 
Ethnicity itself is multidimensional, and it may not be possible to differentiate its 
effect from the risk associated with remoteness, urbanization, lifestyle, education, 
health awareness, and individual income.
3. Social and economic risk factors
Social and economic factors have a fundamental impact on the visual prognosis 
of diabetic eye disease. A number of studies have investigated the negative influ-
ence of deprivation on the prevalence of diabetes, access to evaluation and care, 
level of metabolic control, and rate of complications and were reported in system-
atic reviews for type 1 [19] and type 2 diabetes [20]. Remoteness [odds ratio (OR) 
2.02] and diabetes in combination with never having had an eye examination (OR 
14.47) were among the main risk factors for vision loss in indigenous Australians, 
and blindness prevalence was 2.8 times higher among them than in non-indigenous 
Australians after age and gender adjustment [21]. The presence of PDR was 
associated with low income (OR = 3.6 for developing PDR if income was less than 
$20000) in the Proyecto VER Study in the USA involving 4774 Hispanics over the 
age of 40, after controlling for other factors [22]. Deprivation, as a comprehensive 
measure of income, employment, health and disability, education, crime, barriers 
to housing, services, and living environment at the level of small geographic areas, 
was developed in the UK as a numerical index per residential code and used in a 
large national database study of 79,775 diabetic patients to highlight its effect on 
visual acuity and need for early treatment at first hospital presentation [23]. The 
OR of presenting with “sight impairment” at first visit to the hospital eye service 
was gradually decreasing from 1.29 in the most deprived group to 0.77 in the least 
deprived one, and OR for “severely sight impaired” was 1.17 in the most deprived 
decile versus 0.88 in the least deprived one. The risk of sight-threatening macu-
lopathy and vitreous hemorrhages showed little variations across the deprivation 
range, and tractional retinal detachment was less likely in the two least deprived 
deciles. The large scale of the study and use of “real-world” multicenter in-hospital 
dataset provided statistical strength to the conclusion that the impact of deprivation 
extends to late presentation of retinopathy, significant loss of vision at presentation, 
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and a pattern of advanced retinal complications that affect the treatment these 
patients receive. Financial factors are often self-reported by diabetic patients who 
are missing screening appointments and treatment sessions. However a study in 
Tanzania revealed that the reasons for poor compliance are more complicated. The 
clarity of referral process and ease of navigation through the unfamiliar hospital 
environment are essential, particularly for the elderly and less educated patients 
from remote areas [24]. Another formidable obstacle is the widespread compla-
cency and fatalistic resignation with the notion that retinopathy will inevitably end 
up with blindness. Constant assurance and encouragement that diabetic eye disease 
is a treatable condition with good prognosis is a practical strategy to prevent delays 
in diagnosis of sight-threatening complications. Lack of education greatly affects 
the health awareness and adherence with retinopathy management. In Kuwait, 16% 
of the men and 46% of the women over 65 years are illiterate, and 20% of the men 
and 24% of the women in the same age group can only read and write [25]. This is a 
significant barrier to in-depth understanding and compliance with recommended 
treatment and lifestyle and eventually compromises the visual outcome despite the 
high economic standard of the Kuwaiti nationals and availability of services in the 
country. Family support greatly improves the continuum of care and is essential for 
the regular attendance of the patients, especially females from a more conservative 
background.
Progression of nonproliferative to proliferative disease was investigated 
in several large cohort studies [26, 27]. Disease severity was estimated by the 
EDTRS classification and taken separately for each eye or concatenated as the 
bilateral grade, and progression was defined as the increase of two or more steps 
in severity. The rate of progression to PDR varied greatly—it was from 4 to 9.9% 
in the first 4–5 years and 8–12% in the next 5 years and reached a cumulative 
level of 31% after 16 years and 42% after 25 years in type 1 and type 2 diabet-
ics. There are differences between the populations and methodology applied in 
the hospital-based and community-based studies as more patients with severe 
disease that required active management were probably referred to tertiary care 
centers [28–32].
The diagnosis of diabetic macular edema has evolved with the introduction of 
stereoscopic photography of the posterior pole and optical coherence tomography 
(OCT). The presence of any edema and clinically significant edema (CSME) by the 
modified EDTRS classification has been investigated in multiple hospital series and 
population-based studies. Detection of DME in non-stereoscopic fundus photo-
graphs is less sensitive to milder forms with recent onset, and probably the reported 
prevalence covers the more severe chronic stage. The prevalence of CSME in type 
1 patients was from 5.73% in Spain to 9.4% in Brazil [33, 34]. Among patients with 
type 2 diabetes, it was in the range from 1.4% in Portugal to 12.8% in Denmark [35, 
36]. There are reports indicating that the prevalence of DME in Central and Eastern 
Europe [37], North Africa, and Middle East [38] is considerably higher, and further 
research on the magnitude of CSME and risk factors for its progression will contrib-
ute to the estimates of sight-threatening retinopathy globally.
4. Diabetic nephropathy
Diabetic nephropathy (DN), the primary cause of chronic kidney disease, is 
significantly associated with incidence and progression of diabetic retinopathy 
as demonstrated in Brazilian [39], Spanish [40], Korean [41], Taiwanese Chinese 
[42], and Australian [43] patients. The presence of chronic kidney impairment had 
adjusted a hazard ratio of 5.01 for nonproliferative and 9.7 for proliferative disease 
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as compared to patients without nephropathy. At 5-year follow-up, the hazard 
ratio of progression to PDR was 2.26 in patients with DN, and it was related to the 
levels of microalbuminuria and estimated glomerular filtration rate with cutoff 
below 60 mL/min/1.73 m2 [44]. Hypertension and DN in patients with chronic 
kidney disease increased the risk of progression to proliferative disease; however 
diabetic nephropathy did not significantly affect the development or progression 
of DME. Among the Taiwanese Chinese patients, diabetic macular edema had high 
crude hazard ratio association with cerebrovascular accidents and lesser one for 
hypertension and use of statins; however the significance was lost after controlling 
for age, sex, comorbidities, and medications.
5. Pregnancy in diabetic patients
Diabetes affects 17% of pregnancies worldwide and can be pre-existing type 1, 
gestational, or type 2, in some of the patients—previously undiagnosed. The high-
est rate of diabetes in pregnancy is recorded in Southeast Asia, 25%, and the preva-
lence of pre-existing diabetes is highest among women from the Middle East and 
North Africa—3.1%. Australian mothers who were born in high diabetes risk areas 
such as Polynesia, Asia, and the Middle East are 1.4 times more likely to have type 
2 diabetes during pregnancy [45]. Similarly, in the USA and UK, patients belong-
ing to Black, Asian, Hispanic, and Pacific Island ethnic minorities had higher 
proportion of pre-existing diabetes and pre-existing type 2 DM. Progression of 
retinopathy during pregnancy is related to the level of diabetic retinopathy prior to 
conception and was noted in 58% of the patients with moderate or more severe DR 
at baseline. Duration of diabetes type 1 greater than 15 years and type 2 more than 
6 years was significantly associated with higher rate of progression of retinopathy 
in patients with pre-existing proliferative disease. Poor glycemic control prior and 
during pregnancy was an independent risk factor for retinopathy progression; 
however tight control and rapid optimization of metabolic control in such patients 
were associated with worsening of retinopathy. As the long-term benefits of proper 
glycemic management outweigh the short-term risk of deteriorating retinopathy, 
optimal control is currently recommended prior to and as soon as possible after 
conception for the health of the mother and fetus. Progression of retinopathy dur-
ing pregnancy was significantly higher in diabetic patients with preeclampsia, with 
sight-threatening complications in 50% of the diabetic women with preeclampsia 
compared to 8% without it [46]. Other risk factors for deteriorated retinopathy 
during pregnancy include young age of type 1 onset, insulin treatment in type 
2 prior to pregnancy, low vision at baseline, and pre-existing macular edema at 
baseline [47].
6. Diabetic foot syndrome
Diabetic foot syndrome is one of the important consequences of long-term 
uncontrolled diabetes, which occurs due to a combination of peripheral neuropathy 
and microvasculopathy in the lower extremities. It may vary from a minor ulcer-
ation to necrosis of tissues, sometimes warranting amputation [48]. Several hospital 
series demonstrated the presence of retinopathy in 90–95% and proliferative 
disease and severe nonproliferative changes in 39–55% in such patients independent 
of the ulcer severity [49]. Diabetic foot syndrome in type 1 and type 2 diabetic 
patients with retinopathy was associated with higher levels of HbA1c, serum 
creatinine, older age, and lower hematocrit, particularly elevated in the subgroup 
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with proliferative disease—all characteristics of concomitant chronic kidney disease 
and neuropathy in poorly controlled, long-lasting diabetes. Despite the lack of data 
on macular edema, the presence of any stage of diabetic foot ulcer is emerging as a 
predictor for retinopathy deterioration [50, 51].
7. Depression and anxiety
The overall prevalence of depressive symptoms in diabetic patients with reti-
nopathy is estimated in the range of 35% in China to 50% in African Americans and 
is more prevalent in type 2 [52, 53]. The association between depressive symptoms, 
diabetes, and diabetic retinopathy is likely to be bidirectional: the impairment and 
burden of diabetes and its complications can precipitate depression and vice versa, 
and depression can impair diabetes control through various biological and behav-
ioral pathways [54, 55]. Depression aggregates negative attitudes toward treatment 
and often leads to poorer glycemic control, less adherence to treatment, higher risk 
for PDR, greater morbidity and mortality, and higher costs [56]. Low income has 
been implicated in some research from the USA; however it was not found signifi-
cant in a large cross-sectional study from Australia. Patients with longer duration of 
diabetes, worse glycemic control, lower educational level, and severe vision impair-
ment below 20/63 were associated with greater depression symptoms. Symptoms 
of anxiety were associated with type 1 diabetes, presence of myocardial infarction/
angina, arrhythmia, stroke, asthma, anemia, arthritis or osteoporosis, younger 
age, and female gender [57]. Severe NPDR and PDR, but not macular edema, were 
independently associated with depressive symptoms, and the authors suggest that 
severity of retinopathy could be an indicator to prompt monitoring of depression in 
at-risk diabetic individuals. Antidepressant medications have been associated with 
slowing the progression of retinopathy in diabetic patients. However the outcome 
was limited to subjects with elevated C-reactive protein over 0.3 mg/dL. Selective 
serotonin reuptake inhibitor users had significantly lower risk of developing severe 
retinopathy than non-SSRI users [58]. The results of longitudinal studies show that 
the speed of cognitive decline in type 2 diabetic patients is up to twice as fast as that 
of normal aging individuals and diabetic patients have an increased risk of mild 
cognitive impairment (MCI). In addition, type 2 diabetic patients had an almost 
twofold higher risk of developing Alzheimer’s disease than age-matched nondia-
betic subjects. This increased risk was maintained even after adjusting for vascular 
risk factors. The annual conversion rate from MCI to dementia ranges between 10 
and 30% in the general population, but this is much higher in the type 2 diabetic 
population. The impact of cognitive impairment on the compliance with lifelong 
retinopathy treatment and its outcome needs further evaluation; however clinical 
practice indicates the need for personalized multidisciplinary approach.
8. Progression to vision-threatening retinopathy
The variability in the rate of progression to vision-threatening retinopathy 
and particularly in the response to treatment was noted from the onset of clinical 
and epidemiological studies in diabetic patients and has been attributed to the 
effect of genetic predisposition together with systemic and socioeconomic factors. 
Single-nucleotide polymorphisms [58–60] and genome-wide associations [61–63] 
have been investigated in patients with proliferative disease and macular edema, 
and the results so far are inconclusive mainly due to the size of the samples and the 
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inclusion of cases with coexisting proliferations and edema in the cohorts. Detailed 
assessment in the polymorphisms of the VEGF gene revealed that some of them 
are related to higher susceptibility to severe retinopathy, but not to the outcome 
of ranibizumab intravitreal injections [64] in contrast to an earlier report on the 
response to bevacizumab [65]. In order to confirm the association of several novel 
genetic loci with severe retinopathy, replication studies and extension in additional 
cohorts and ethnic groups have been recommended [66]. Research of systemic and 
retinal inflammation as risk factors for DR and DME [67, 68], upregulated leptin 
[69, 70] and adiponectin [71], oxidative stress [72], and vitamin D deficiency [73] 
has provided significant associations. Reliable and accessible markers of these 
factors can be important predictors of the disease severity and progression and 
thus provide early guidance in personalizing the monitoring and treatment of the 
patients at risk of vision loss.
9. Management of DME
The introduction of intravitreal anti-VEGF drugs and corticosteroid implants 
revolutionized the management of DME. Prospective randomized clinical trials 
have addressed the efficacy and safety of different types of agents and administra-
tion regimens and have shown wide variations in terms of visual acuity gain. In 
the DRCR.net trial, after 2 years of treatment, approximately 98% of the patients 
maintained their visual acuity and attained visual gain in 37% of the patients on 
ranibizumab, 35% of those on bevacizumab, and 39% of those on aflibercept [74]. 
Stratified analysis of RESTORE in DME, RETAIN, and Protocol I demonstrated 
that the most significant gain in number of EDTRS letters after 12–36 months 
was in patients with baseline BCVA 60 and less letters in the range of 8.6–10.36 
letters, versus the gain for patients with baseline BCVA 61–71 letters who achieved 
7.96–4.36 letters, and the least gain of 5.42–4.2 letters was in the group with base-
line BCVA better that 73 letters [75]. Thus, the patients with most severe vision 
deterioration and baseline BCVA in the range of 20/320–20/63 who responded 
favorably to 2 years of intensive therapy improved to BCVA from 20/160 to 20/40. 
High visual acuity in the range of 20/40–20/32 was achieved only in patients with 
baseline BCVA over 20/30 despite the small number of gained EDTRS letters. The 
range and stability of this visual improvement depended on increasing age, level 
of glycemic control, and previous panretinal photocoagulation [76]. OCT mark-
ers of better functional outcome after anti-VEGF treatment were the presence of 
intact ellipsoid zone and lack of hyperreflective spots or disruption of the inner 
retinal layers, which are seen in patients with more recent onset of the edema and 
no previous macular grid laser [77]. Patients with chronic macular edema had 
considerably better functional and structural results after treatment with steroid 
implants. Visual gain of more than 15 letters was achieved in 22% after 3 years on 
intravitreal dexamethasone [78] and in 34% after 3 years on fluocinolone aceton-
ide [79]. Eyes with submacular fluid, no hyperreflective foci, and a continuous 
IS-OS layer responded better to dexamethasone implants with gain of 10 or more 
letters after 2 and 4 months [80]. The adverse effects of both implants included 
the formation of cataract, 13–50% after 1 year on dexamethasone and 82% after 
3 years on fluocinolone acetonide, and intraocular pressure rise over 25 mmHg 
in 42% of the eyes with dexamethasone and 38% with fluocinolone acetonide; 
however a small percentage required glaucoma surgery—0.5% of the eyes with 
dexamethasone and 4.8% with fluocinolone acetonide. Patients with poorly 
controlled diabetes and DME, severe nonproliferative or proliferative disease, 
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epimacular membranes, myopia, glaucoma, and various degrees of cataract are 
excluded from the randomized clinical trials; however such cases are predominant 
in real-world practice and add new dimensions to the challenge of visual rehabili-
tation. Analysis of large electronic medical record databases from the USA [81] 
and Korea [82] demonstrated visual outcomes that are meaningfully inferior to 
those in the clinical trials and were attributed to undertreatment and lack of close 
monitoring. A sizable group of DME patients were lost to follow-up in the initial 
stages of anti-VEGF treatment—25% were reported from a single retina practice in 
the USA and the main risk factors were being Hispanic, Black, or a Pacific islander; 
low income, AGI less than $50,000; and decreasing baseline visual acuity [83]. In 
a study of European DME patients, 46% had at least one break-off in their anti-
VEGF treatment for more than 100 days, and the most common reason for poor 
compliance was comorbidity. In 60% of these cases, the visual acuity deteriorated 
significantly after the break [84]. Prevention of vision loss from diabetic macular 
edema is achievable with the current therapeutic modalities; however it requires 
very early identification at stages with relatively high visual acuity and needs the 
introduction of best-corrected visual acuity and OCT in the screening protocol. As 
shown in the Protocol G—Subclinical DME study of the DRCR.net that involved 
a longitudinal assessment of eyes that had retinal thickening on OCT without 
thickening on clinical exam, a progression to clinically apparent DME was seen in 
23–58% of eyes within 2 years.
10. Management of proliferative disease
Vision loss in approximately 25% of patient with diabetic retinopathy is associ-
ated with complications of proliferative disease. An estimated 17 million diabetic 
people worldwide have PDR [17], and without treatment more than half of the 
patients with high-risk PDR will be blind within 5 years. Panretinal photocoagula-
tion was established as an effective treatment to reduce by 50% the incidence of 
severe vision loss, if performed prior to the development of vitreous hemorrhages 
and tractional retinal detachment [85]. Still, the EDTRS has shown that 5% of 
patients with PDR will require vitreous surgery despite having received adequate 
PRP [86]. The Diabetic Retinopathy Vitrectomy Study validated the superiority of 
vitrectomy over observation; however despite the fact that the trial did not include 
patients with macula, involving traction, the visual outcome was low. Subsequent 
studies on vitrectomy for PDR reported that between 10 and 20% of the patients 
did not improve their visual acuity above hand motion or less [87]. Favorable 
factors for visual rehabilitation after vitrectomy for macula-involving tractional 
retinal detachment included short duration of detachment, previous panretinal 
photocoagulation, and lack of severe neovascularization and vitreous hemorrhage. 
Predictors of poor visual results were iris neovascularization and neovascular glau-
coma, papillo-vitreal traction, baseline visual acuity below 20/200, initial macular 
detachment, intraoperative iatrogenic break, or use of heavy silicone oil [88–90]. 
Functional outcome was significantly affected in patients with postoperative macu-
lar ischemia, recurrent vitreous hemorrhage, optic atrophy, epiretinal membranes, 
and recurrent retinal detachment [91, 92]. The introduction of small-gauge vitrec-
tomy instruments and trans-scleral cannulas enabled the fast and effective removal 
of most fibrovascular membranes with the vitrectomy probe applying the lift and 
shave technique [93]. Visual outcomes were poorer in older age group, tractional 
retinal detachments involving macula and eyes with extensive membranes and with 
silicone oil as tamponade; however both 23-gauge and 25-gauge groups were com-
parable in relation to visual improvement, anatomical success, and intraoperative 
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and postoperative complications [94]. The integration of swept-source optical 
coherence tomography and digital displays can provide important guidance dur-
ing surgery for PDR complications and facilitate decision-making [95]; however 
further research will show whether these technological advances will translate into 
better postoperative visual outcome.
Medical treatment for PDR has had minimal advancement over the past 40 years 
since the wide acceptance of panretinal photocoagulation in the early management 
of the disease. Regression of proliferative activity was noted in eyes treated with 
anti-VEGF for concomitant macular edema [96] and that lead to a series of trials 
on aflibercept and ranibizumab versus panretinal photocoagulation in the manage-
ment of PDR. Both drugs were superior to PRP in 1 [97] and 2 years [98] in terms 
of visual acuity and visual field sensitivity. Assessment of the peripapillary retinal 
nerve fiver layer thickness in patients treated with ranibizumab revealed reduction 
that was due to decreased edema rather than loss of axons [99]. Patients with mild 
and moderate vitreous hemorrhages treated with ranibizumab had significantly less 
need for vitrectomy, less recurrences of hemorrhage, and better visual acuity on all 
follow-up visits than the patient under observation or operated for non-resolving or 
aggravated hemorrhages [100]. However, despite the improvement in retinopathy 
severity on color photographs, the retinal perfusion did not improve on wide-field 
fluorescein angiography that revealed no reperfusion of small vessels in areas of 
previous capillary non-perfusion [101]. Diabetic patients are prone to significant 
loss to follow up due to illness, financial hardship, and lack of compliance. The rate 
of complications and loss of vision after unintentional interruptions for more than 
6 months in PDR patients treated only on anti-VEGF was considerably higher than 
the eyes that received PRP, with a significantly higher number of eyes with trac-
tional retinal detachment and neovascularization of the iris [102]. In a retrospective 
review of 13 eyes treated exclusively with anti-VEGF for PDR with or without 
macular edema or severe NPDR with macular edema, with hiatus of 12 months, 9 
presented with vitreous hemorrhage, 5 with neovascular glaucoma, and 4 with trac-
tional retinal detachment. Despite the aggressive treatment of the complications, 10 
eyes lost more than 3 lines of vision, and 2 had final vision hand motions [103]. So, 
while anti-VEGF proved to be effective for PDR in the clinical trials, in real-world 
the unclear long-term advantages of pharmacological monotherapy over PRP, the 
increased cost, and treatment burden are not optimal for many diabetic patients.
Neovascular glaucoma is a late complication of proliferative disease with chronic 
ischemia in the posterior segment and development of a fibrovascular membrane 
on the anterior surface of the iris and iridocorneal angle of anterior chamber, and 
usually its onset correlates with poor glycemic control. In the early stages, iris 
neovascularization can be found without elevated IOP. Panretinal photocoagulation 
remains the mainstay in controlling the neovascular drive and should be considered 
in all cases of neovascularization of the anterior segment when retinal ischemia is 
present. After panretinal photocoagulation, complete regression of retinal neo-
vascularization can be reached in 67–77% of cases, visual loss can be prevented 
in 59–73%, and IOP reduction can be achieved in 42% [104]. Anti-VEGF injec-
tions can lead to regression of both iris and angle neovascularization and improve 
intraocular pressure control when the angle remains open. However, the effects of 
anti-VEGF agents seemed to induce only a temporary regression of new vessels in 
the anterior chamber angle and IOP reduction, generally lasting between 4 and 6 
weeks [105]. Glaucoma drainage devices are usually considered the first treatment 
option for refractory glaucoma. Neovascular glaucoma patients are at greater risk 
for surgical failure after glaucoma valve surgery compared with non-neovascular 
glaucoma controls. A recent retrospective, comparative, case series of 163 eyes of 
151 patients with neovascular glaucoma included 99 treated without and 64 treated 
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with intravitreal bevacizumab. IOP decreased to 18.3 ± 13.8 mmHg in the non-
bevacizumab group and 15.3 ± 8.0 mmHg in the bevacizumab group. Panretinal 
photocoagulation substantially reduced the need for glaucoma surgery (P < 0.001) 
in bevacizumab-treated eyes. Therefore, although bevacizumab delayed the need 
for glaucoma surgery, panretinal photocoagulation was the most important factor 
that reduced the need for surgery. Vision and IOP in eyes with neovascular glau-
coma treated with bevacizumab showed no long-term differences when compared 
with eyes that were not treated with bevacizumab. Thus, intravitreal anti-VEGF 
drugs serve as an effective temporizing treatment but are not a replacement for 
close monitoring and definitive treatment of neovascular glaucoma [106, 107].
Impairment of vision in diabetic patients is not limited to retinopathy—the 
leading causes of deteriorated vision and progression of vision loss in a cohort from 
South India were cataracts and uncorrected refractive errors [108]. The introduc-
tion of phacoemulsification significantly reduced the surgical trauma and leads 
to a growing tendency toward earlier cataract surgery in diabetic patients [109]. 
This approach facilitates panretinal photocoagulation and allows for the identifica-
tion and adequate treatment of diabetic macular edema before and after cataract 
surgery. Preexisting macular edema can increase the risk of edema progression by 
20–50%, and intravitreal anti-VEGF agents are recommended perioperatively [110]. 
Steroids, on the other hand, have been shown to be effective for persistent or refrac-
tory diabetic macular edema prior to and after cataract procedures. Dexamethasone 
implants and fluocinolone implants resulted in significant improvement in clinically 
significant macular edema and visual outcomes [111]. Despite the advancement in 
phacoemulsification technology, poor visual acuity following cataract extraction is 
still common in patients with diabetes. Posterior capsule opacification, postopera-
tive cystoid macular edema, diabetic macular edema [112], and worsening of the 
DR are the main complications seen in diabetic patients. According to the Early 
Treatment of Diabetic Retinopathy Study, the presence of clinically significant 
diabetic macular edema at the time of cataract surgery was significantly associated 
with poor visual acuity and was a predictor of final visual acuity worse than 20/200 
following uncomplicated phacoemulsification [113]. The severity of DR at the time 
of cataract surgery is also a significant determinant of postoperative VA; more 
severe retinopathy seems to be associated with an increased prevalence of macular 
ischemia or edema and a reduced tendency for spontaneous resolution of postop-
erative macular edema with associated poor postoperative VA. Treatment-naïve 
PDR before cataract surgery may progress to vitreous hemorrhage and tractional 
retinal detachment following phacoemulsification, thus threatening good visual 
outcome [114].
In conclusion, vision loss due to diabetic complications in the eye is growing 
worldwide despite availability of screening programs, advanced diagnostic tools, 
pharmacotherapy, and rapidly evolving surgical technology. Prevention requires:
• Identification of the social groups and individuals at high risk of vision- 
threatening diabetic complications
• Coverage with diabetic retinopathy screening with introduction of AI tools, 
wide-field retinal assessment, telemedicine, and OCT of the posterior segment
• Outreach of qualified management closer to the diabetic patients’ communities
• Early, intensive management before significant vision loss
• Lifetime, highly qualified monitoring and early management of complications
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